John C Oertle
Envita Medical Center, USA
Title: The natural product, PGP-x1, its role in inhibition of P-glycoprotein and MDR-1 overexpression and its role as an adjuvant treatment of late stage solid tumors
Biography
Biography: John C Oertle
Abstract
Resistance to chemotherapy after successive dosing regimens is a common theme for cancer progression that all oncologists
face. Similarly, the resistance to antimicrobial agents on infections can render similar complications especially with the
broad use of antibiotics. P-glycoprotein (Pgp), also known as multidrug resistance protein 1 (MDR-1), is found on the surface
membrane of both bacteria and mammalian cells, and acts to remove toxins or other harmful agents from the cell. Thus,
inhibition of Pgp and MDR-1 as a treatment adjuvant is of great interest within the fields of oncology and infectious disease
alike.
There are several naturally occurring agents that forego an inhibitory effect on MDR-1 and Pgp with varying amount of
literature to support its claims. As attractive as these previously noted natural agents have on inhibition of MDR-1, preliminary
data suggests a pattern may emerge from clinical data obtained from a natural supplement PGP-x1 utilizing a plant alkaloid.
Its active constituents have led to promising research revealing data which suggest it enhances chemotherapy and antibiotic
treatment via a mechanism involving the inhibition of MDR-1, Pgp and MRP-1 related transport. The data is consistent in
several experimental models that show the active alkaloid has the ability to inhibit expression of Pgp in cancer cells. The active
ingredient used in PGP-x1, which was utilized in the patient case studies to be discussed, utilizes a proprietary extraction
methodology. Each patient in this cohort of case studies was identified to have overexpression of MDR-1 resistance. They were
treated with genetically targeted chemotherapy in a metronomic dosing strategy with insulin as a biological response modifier
concomitantly with PGP-x1.